Previously Presented News Today

In Apotex, Inc. v. Auspex Pharms., Inc., IPR2021-01507, Paper 9 (P.T.A.B. March 9, 2022), the Patent Trial and Appeal Board exercised its discretion under 35 U.S.C. § 325(d) to deny institution of Apotex's petition for inter partes review.

STAFFORD, Texas--(BUSINESS WIRE)--Apr 10, 2021-- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today presented a poster of the final 5 year GP2 Phase IIb clinical trial immune response data at the 2021 AACR Annual Meeting. Immune response is the primary mechanism of action for GP2 and is cr...